Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

764 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ; RAD B253 Study Group. Viganò M, et al. J Heart Lung Transplant. 2007 Jun;26(6):584-92. doi: 10.1016/j.healun.2007.03.005. Epub 2007 Apr 27. J Heart Lung Transplant. 2007. PMID: 17543781 Clinical Trial.
Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study.
Podesser BK, Rinaldi M, Yona NA, Pulpón LA, Villemot JP, Haverich A, Duveau D, Brandrup-Wognsen G, Gronda E, Costard-Jäckle A, Crespo-Leiro MG, Khazen CS, Viganó M, Segovia J, Mattei MF, Harringer W, Treilhaud M, Karason K, Mangiavacchi M, Laufer G. Podesser BK, et al. Among authors: vigano m. Transplantation. 2005 Jan 15;79(1):65-71. doi: 10.1097/01.tp.0000140965.83682.d6. Transplantation. 2005. PMID: 15714171 Clinical Trial.
Heart rate and cardiac allograft vasculopathy in heart transplant recipients.
Olmetti F, Pinna GD, Maestri R, D'Armini A, Pellegrini C, Viganò M, Lilleri D, Gerna G, Febo O, La Rovere MT. Olmetti F, et al. Among authors: vigano m. J Heart Lung Transplant. 2011 Dec;30(12):1368-73. doi: 10.1016/j.healun.2011.07.009. Epub 2011 Aug 15. J Heart Lung Transplant. 2011. PMID: 21840733
Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF; RAD A2411 Study Investigators. Viganò M, et al. Transpl Infect Dis. 2010 Feb;12(1):23-30. doi: 10.1111/j.1399-3062.2009.00448.x. Epub 2009 Sep 9. Transpl Infect Dis. 2010. PMID: 19744284 Clinical Trial.
Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation.
Segovia J, Gerosa G, Almenar L, Livi U, Viganò M, Arizón JM, Yonan N, Di Salvo TG, Renlund DG, Kobashigawa JA; ERL 2401 Study Group. Segovia J, et al. Among authors: vigano m. Clin Transplant. 2008 Nov-Dec;22(6):809-14. doi: 10.1111/j.1399-0012.2008.00887.x. Epub 2008 Aug 12. Clin Transplant. 2008. PMID: 18702660 Clinical Trial.
764 results